

REMARKS/ARGUMENTS

Claims 4, 6-10, 16, 19-22, 25, and 28 are pending in this application. Claims 12-15 and 17 were withdrawn from consideration, as drawn to non-elected matter and have been cancelled.

Claims 9, 16 and 20 have been amended to define the antibody as a humanized antibody as presented, in part, in previously presented claims 5 and 20.


No new matter is believed to have been added by this amendment.

Applicants reiterate their position that the claims are enabled and described, and particularly for the humanized antibody claimed herein. Further, Applicants state that there is insufficient evidence to demonstrate that the cited prior art inherently (i.e., each and every time) achieve what is now claimed.

Reconsideration of the outstanding rejections in light of the amendments and remarks contained herein is requested.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Daniel J. Pereira
Registration No. 45,518

Customer Number
22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 08/07)